Cargando…

Restoration of type 1 iodothyronine deiodinase expression in renal cancer cells downregulates oncoproteins and affects key metabolic pathways as well as anti-oxidative system

Type 1 iodothyronine deiodinase (DIO1) contributes to deiodination of 3,5,3’,5’-tetraiodo-L-thyronine (thyroxine, T4) yielding of 3,5,3’-triiodothyronine (T3), a powerful regulator of cell differentiation, proliferation, and metabolism. Our previous work showed that loss of DIO1 enhances proliferati...

Descripción completa

Detalles Bibliográficos
Autores principales: Popławski, Piotr, Wiśniewski, Jacek R., Rijntjes, Eddy, Richards, Keith, Rybicka, Beata, Köhrle, Josef, Piekiełko-Witkowska, Agnieszka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741248/
https://www.ncbi.nlm.nih.gov/pubmed/29272308
http://dx.doi.org/10.1371/journal.pone.0190179
_version_ 1783288167712948224
author Popławski, Piotr
Wiśniewski, Jacek R.
Rijntjes, Eddy
Richards, Keith
Rybicka, Beata
Köhrle, Josef
Piekiełko-Witkowska, Agnieszka
author_facet Popławski, Piotr
Wiśniewski, Jacek R.
Rijntjes, Eddy
Richards, Keith
Rybicka, Beata
Köhrle, Josef
Piekiełko-Witkowska, Agnieszka
author_sort Popławski, Piotr
collection PubMed
description Type 1 iodothyronine deiodinase (DIO1) contributes to deiodination of 3,5,3’,5’-tetraiodo-L-thyronine (thyroxine, T4) yielding of 3,5,3’-triiodothyronine (T3), a powerful regulator of cell differentiation, proliferation, and metabolism. Our previous work showed that loss of DIO1 enhances proliferation and migration of renal cancer cells. However, the global effects of DIO1 expression in various tissues affected by cancer remain unknown. Here, the effects of stable DIO1 re-expression were analyzed on the proteome of renal cancer cells, followed by quantitative real-time PCR validation in two renal cancer-derived cell lines. DIO1-induced changes in intracellular concentrations of thyroid hormones were quantified by L-MS/MS and correlations between expression of DIO1 and potential target genes were determined in tissue samples from renal cancer patients. Stable re-expression of DIO1, resulted in 26 downregulated proteins while 59 proteins were overexpressed in renal cancer cells. The ‘downregulated’ group consisted mainly of oncoproteins (e.g. STAT3, ANPEP, TGFBI, TGM2) that promote proliferation, migration and invasion. Furthermore, DIO1 re-expression enhanced concentrations of two subunits of thyroid hormone transporter (SLC7A5, SLC3A2), enzymes of key pathways of cellular energy metabolism (e.g. TKT, NAMPT, IDH2), sex steroid metabolism and anti-oxidative response (AKR1C2, AKR1B10). DIO1 expression resulted in elevated intracellular concentration of T4. Expression of DIO1-affected genes strongly correlated with DIO1 transcript levels in tissue samples from renal cancer patients as well as with their poor survival. This first study addressing effects of deiodinase re-expression on proteome of cancer cells demonstrates that induced DIO1 re-expression in renal cancer robustly downregulates oncoproteins, affects key metabolic pathways, and triggers proteins involved in anti-oxidative protection. This data supports the notion that suppressed DIO1 expression and changes in local availability of thyroid hormones might favor a shift from a differentiated to a more proliferation-prone state of cancer tissues and cell lines.
format Online
Article
Text
id pubmed-5741248
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-57412482018-01-08 Restoration of type 1 iodothyronine deiodinase expression in renal cancer cells downregulates oncoproteins and affects key metabolic pathways as well as anti-oxidative system Popławski, Piotr Wiśniewski, Jacek R. Rijntjes, Eddy Richards, Keith Rybicka, Beata Köhrle, Josef Piekiełko-Witkowska, Agnieszka PLoS One Research Article Type 1 iodothyronine deiodinase (DIO1) contributes to deiodination of 3,5,3’,5’-tetraiodo-L-thyronine (thyroxine, T4) yielding of 3,5,3’-triiodothyronine (T3), a powerful regulator of cell differentiation, proliferation, and metabolism. Our previous work showed that loss of DIO1 enhances proliferation and migration of renal cancer cells. However, the global effects of DIO1 expression in various tissues affected by cancer remain unknown. Here, the effects of stable DIO1 re-expression were analyzed on the proteome of renal cancer cells, followed by quantitative real-time PCR validation in two renal cancer-derived cell lines. DIO1-induced changes in intracellular concentrations of thyroid hormones were quantified by L-MS/MS and correlations between expression of DIO1 and potential target genes were determined in tissue samples from renal cancer patients. Stable re-expression of DIO1, resulted in 26 downregulated proteins while 59 proteins were overexpressed in renal cancer cells. The ‘downregulated’ group consisted mainly of oncoproteins (e.g. STAT3, ANPEP, TGFBI, TGM2) that promote proliferation, migration and invasion. Furthermore, DIO1 re-expression enhanced concentrations of two subunits of thyroid hormone transporter (SLC7A5, SLC3A2), enzymes of key pathways of cellular energy metabolism (e.g. TKT, NAMPT, IDH2), sex steroid metabolism and anti-oxidative response (AKR1C2, AKR1B10). DIO1 expression resulted in elevated intracellular concentration of T4. Expression of DIO1-affected genes strongly correlated with DIO1 transcript levels in tissue samples from renal cancer patients as well as with their poor survival. This first study addressing effects of deiodinase re-expression on proteome of cancer cells demonstrates that induced DIO1 re-expression in renal cancer robustly downregulates oncoproteins, affects key metabolic pathways, and triggers proteins involved in anti-oxidative protection. This data supports the notion that suppressed DIO1 expression and changes in local availability of thyroid hormones might favor a shift from a differentiated to a more proliferation-prone state of cancer tissues and cell lines. Public Library of Science 2017-12-22 /pmc/articles/PMC5741248/ /pubmed/29272308 http://dx.doi.org/10.1371/journal.pone.0190179 Text en © 2017 Popławski et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Popławski, Piotr
Wiśniewski, Jacek R.
Rijntjes, Eddy
Richards, Keith
Rybicka, Beata
Köhrle, Josef
Piekiełko-Witkowska, Agnieszka
Restoration of type 1 iodothyronine deiodinase expression in renal cancer cells downregulates oncoproteins and affects key metabolic pathways as well as anti-oxidative system
title Restoration of type 1 iodothyronine deiodinase expression in renal cancer cells downregulates oncoproteins and affects key metabolic pathways as well as anti-oxidative system
title_full Restoration of type 1 iodothyronine deiodinase expression in renal cancer cells downregulates oncoproteins and affects key metabolic pathways as well as anti-oxidative system
title_fullStr Restoration of type 1 iodothyronine deiodinase expression in renal cancer cells downregulates oncoproteins and affects key metabolic pathways as well as anti-oxidative system
title_full_unstemmed Restoration of type 1 iodothyronine deiodinase expression in renal cancer cells downregulates oncoproteins and affects key metabolic pathways as well as anti-oxidative system
title_short Restoration of type 1 iodothyronine deiodinase expression in renal cancer cells downregulates oncoproteins and affects key metabolic pathways as well as anti-oxidative system
title_sort restoration of type 1 iodothyronine deiodinase expression in renal cancer cells downregulates oncoproteins and affects key metabolic pathways as well as anti-oxidative system
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741248/
https://www.ncbi.nlm.nih.gov/pubmed/29272308
http://dx.doi.org/10.1371/journal.pone.0190179
work_keys_str_mv AT popławskipiotr restorationoftype1iodothyroninedeiodinaseexpressioninrenalcancercellsdownregulatesoncoproteinsandaffectskeymetabolicpathwaysaswellasantioxidativesystem
AT wisniewskijacekr restorationoftype1iodothyroninedeiodinaseexpressioninrenalcancercellsdownregulatesoncoproteinsandaffectskeymetabolicpathwaysaswellasantioxidativesystem
AT rijntjeseddy restorationoftype1iodothyroninedeiodinaseexpressioninrenalcancercellsdownregulatesoncoproteinsandaffectskeymetabolicpathwaysaswellasantioxidativesystem
AT richardskeith restorationoftype1iodothyroninedeiodinaseexpressioninrenalcancercellsdownregulatesoncoproteinsandaffectskeymetabolicpathwaysaswellasantioxidativesystem
AT rybickabeata restorationoftype1iodothyroninedeiodinaseexpressioninrenalcancercellsdownregulatesoncoproteinsandaffectskeymetabolicpathwaysaswellasantioxidativesystem
AT kohrlejosef restorationoftype1iodothyroninedeiodinaseexpressioninrenalcancercellsdownregulatesoncoproteinsandaffectskeymetabolicpathwaysaswellasantioxidativesystem
AT piekiełkowitkowskaagnieszka restorationoftype1iodothyroninedeiodinaseexpressioninrenalcancercellsdownregulatesoncoproteinsandaffectskeymetabolicpathwaysaswellasantioxidativesystem